Levossimendano Altan (Levosimendan)

Levosimendan enhances cardiac contractility by sensitising troponin C to calcium, which increases the force of contraction without raising intracellular calcium levels. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, thereby improving overall heart performance.

The dosing regimen for Levossimendano Altan is determined by the treating physician based on the patient’s clinical status, weight, and response. The prescriber selects the appropriate loading and maintenance infusion rates in accordance with approved guidelines and local practice.

Safety data for levosimendan during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Levosimendan differs from traditional catecholamine inotropes such as dobutamine by increasing contractility through calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of arrhythmias. Additionally, its vasodilatory effect can lower after‑load, whereas dobutamine primarily raises heart rate and contractility without significant vasodilation.

The product must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until ready for preparation and use to maintain stability and potency.

Levossimendano Altan is given as an intravenous infusion. After reconstitution according to the manufacturer’s instructions, a loading dose may be administered over 10 minutes followed by a continuous maintenance infusion, all under continuous hemodynamic monitoring in a critical‑care environment.

The most serious adverse events include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare cases of anaphylactic reactions. Clinicians should monitor blood pressure, cardiac rhythm, and signs of ischemia closely throughout the infusion and be prepared to intervene promptly if these events occur.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure <90 mmHg), obstructive cardiac lesions such as severe aortic stenosis, recent myocardial infarction with ongoing ischemia, and in individuals with known hypersensitivity to the drug or any of its excipients.